A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy
Authors:
- Gbolahan Mbbs OlatunjiGOGbolahan Mbbs Olatunji
- Emmanuel Mbbs KokoriEKEmmanuel Mbbs Kokori
- Israel Charles Mbbs AbrahamIAIsrael Charles Mbbs Abraham
- Oluwatobi Mbbs OmoworareOOOluwatobi Mbbs Omoworare
- Doyin OlatunjiDODoyin Olatunji
- Chimezirim Mbbs EzeanoCEChimezirim Mbbs Ezeano
- Babawale Mbbs Emmanuel AdeobaBABabawale Mbbs Emmanuel Adeoba
- Anthony Chidera Mbbs StanleyAnthony Chidera Mbbs Stanley
- Awoyinfa Michael Mbbs OluwatobilobaAOAwoyinfa Michael Mbbs Oluwatobiloba
- Omidiran Basit Mbbs OluwademiladeOOOmidiran Basit Mbbs Oluwademilade
- Kale Mekoya Mbbs ShimelisKSKale Mekoya Mbbs Shimelis
- Olawale Mbbs OlanisaOOOlawale Mbbs Olanisa
Open Access
- 28 June 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (26) , e38767
Abstract
Hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis), known as Corino de Andrade disease, is a rare neurodegenerative disorder with a significant global impact characterized by the misfolding of transthyretin (TTR) protein leading to amyloid aggregation, ATTRv amyloidosis, especially with polyneuropathy, poses a considerable challenge in managing its rapid progression and debilitating effects. This mini-review focuses on the recent advancements in the treatment landscape for ATTRv amyloidosis with polyneuropathy, specifically the RNA interference therapeutic Vutrisiran and the ligand-conjugated antisense oligonucleotide Eplontersen. We aim to provide a comprehensive overview of the mechanisms, current evidence from clinical trials, and future directions for these novel therapeutic agents. Vutrisiran and Eplontersen have demonstrated significant clinical efficacy in improving neuropathic impairment, quality of life, and serum TTR levels in various trials. The distinct mechanistic approaches of these therapies, coupled with their acceptable safety profiles, offer promising avenues for addressing the complexities of ATTRv amyloidosis with polyneuropathy. The introduction of Vutrisiran and Eplontersen marks a pivotal moment in the quest for effective therapies against ATTRv amyloidosis with polyneuropathy. While clinical evidence is promising, ongoing research is crucial to deepen mechanistic understanding and address research gaps. Future perspectives include the potential expansion of therapeutic options and a more inclusive approach to cater to the diverse needs of individuals globally. This mini-review provides valuable insights into the evolving landscape of ATTRv amyloidosis management and sets the stage for further exploration in this challenging domain.Keywords
This publication has 18 references indexed in Scilit:
- Efficacy and Safety of Acoramidis in Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2024
- Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of EplontersenNeurology and Therapy, 2022
- Vutrisiran: First ApprovalDrugs, 2022
- Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trialAmyloid, 2022
- Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter FutureNeurotherapeutics, 2021
- Ligand Conjugated Antisense Oligonucleotide for the Treatment of Transthyretin Amyloidosis: Preclinical and Phase 1 DataESC Heart Failure, 2020
- A Narrative Review of the Role of Transthyretin in Health and DiseaseNeurology and Therapy, 2020
- Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy SubjectsClinical Pharmacology & Therapeutics, 2020
- Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisNew England Journal of Medicine, 2018
- Repurposing Diflunisal for Familial Amyloid PolyneuropathyJAMA, 2013